Clinical Report: Can an antibody aid neuropsychiatric SLE diagnosis?

Overview

Cerebrospinal fluid antisuprabasin antibody demonstrates greater diagnostic accuracy for neuropsychiatric systemic lupus erythematosus (NPSLE) compared to traditional markers.

Background

Neuropsychiatric systemic lupus erythematosus (NPSLE) presents a diagnostic challenge due to overlapping symptoms with other conditions. Accurate identification is crucial for appropriate management and treatment. The study evaluates the diagnostic performance of cerebrospinal fluid antisuprabasin antibody in a cohort of SLE patients with neuropsychiatric symptoms.

Data Highlights

Key Findings

• Cerebrospinal fluid antisuprabasin antibody had an area under the curve (AUC) of 0.830 for identifying NPSLE.
• At a cutoff of 76.36 ng/mL, the antibody demonstrated 81% sensitivity and 74% specificity.
• Combining CSF antisuprabasin antibody with other markers improved diagnostic AUC to 0.892.
• CSF concentrations of antisuprabasin antibody varied significantly among diagnostic groups, unlike serum concentrations.
• The study included 148 patients who met the 2019 EULAR/ACR classification criteria for SLE.

Clinical Implications

The findings suggest that cerebrospinal fluid antisuprabasin antibody may serve as a valuable biomarker for diagnosing NPSLE in patients with SLE. Clinicians should consider its use alongside traditional diagnostic methods to enhance accuracy.

Conclusion

Cerebrospinal fluid antisuprabasin antibody shows promise as a diagnostic tool for NPSLE, warranting further multicenter studies to validate its clinical utility.

Related Resources & Content

1. Fan Zhang et al., Lupus Science & Medicine, 2023 -- Can an antibody aid neuropsychiatric SLE diagnosis?
2. Clinical Rheumatology — Exploring the Implications of Negative ANA-IIF Results in Patients with Systemic Lupus Erythematosus
3. Journal of General Internal Medicine — Relying on Positive Autoimmune Serology in Patients with Multiple Symptoms
4. Clinical Rheumatology — The Role of Serum APRIL, BAFF, and IL-10 Levels in Assessing Disease Activity and Flare Prediction in Systemic Lupus Erythematosus Is Limited
5. Arthritis Care & Research — Diagnostic Use of Testing for Novel Murine Autoantibodies for Sjögren Disease in the Rheumatology Outpatient Setting
6. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
7. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes - 1999
8. Diagnostic value of cerebrospinal fluid antisuprabasin antibody in neuropsychiatric systemic lupus erythematosus - PMC